Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE

The FDA has approved Moderna's mNEXSPIKE (mRNA-1283) COVID-19 vaccine for adults 65 and older, and individuals aged 12-64 with underlying risk factors. In a Phase 3 trial, mNEXSPIKE demonstrated a 9.3% higher relative vaccine efficacy compared to Moderna's original Spikevax vaccine in individuals 12 and older, and a 13.5% higher relative efficacy in adults 65 and older, with a similar safety profile. Moderna anticipates availability for the 2025-2026 respiratory virus season, positioning mNEXSPIKE alongside Spikevax and mRESVIA, their RSV vaccine, pending regulatory reviews in other markets.

Analysis

Moderna, Inc. (NASDAQ:MRNA) has received U.S. Food and Drug Administration (FDA) approval for mNEXSPIKE (mRNA-1283), its third commercial product, a new COVID-19 vaccine for adults 65 and older, and high-risk individuals aged 12-64. This approval is significant as mNEXSPIKE demonstrated superior efficacy in a Phase 3 trial compared to Moderna's original Spikevax vaccine (mRNA-1273), showing a 9.3% higher relative vaccine efficacy (rVE) in individuals aged 12 and older, and a more pronounced 13.5% higher rVE in adults aged 65 and older. Crucially, mNEXSPIKE exhibited a similar safety profile to Spikevax, with fewer local reactions reported. The company anticipates mNEXSPIKE will be available for the 2025-2026 respiratory virus season in the U.S., complementing its existing Spikevax and mRESVIA (RSV vaccine) offerings. This development diversifies Moderna's respiratory vaccine portfolio and addresses the ongoing public health concern of COVID-19, which, as stated by CEO Stéphane Bancel, resulted in over 47,000 U.S. deaths last year. Furthermore, mNEXSPIKE is currently under review by regulatory authorities in multiple international markets, suggesting potential for expanded global reach.

Key Decisions for Investors

• The FDA approval of mNEXSPIKE, with its demonstrated higher relative vaccine efficacy, particularly in the elderly, positions Moderna to potentially capture additional market share in the COVID-19 vaccine space and strengthen its revenue outlook for the 2025-2026 respiratory season.
• Investors should closely monitor the outcomes of pending regulatory reviews for mNEXSPIKE in international markets, as approvals beyond the U.S. could significantly broaden its commercial footprint and impact future earnings.